Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.80 |
| ▸ | MAOB | P27338 | 9/20 | 0.74 |
| ▸ | MAOA | P21397 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | STK17B | O94768 | 1/20 | 0.62 |
| ▸ | ALPL | P05186 | 1/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ALPG | P10696 | 1/20 | 0.62 |
| ▸ | CDK4 | P11802 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sappanone A SCHEMBL29651769 | 1.00 | MIF (0.80) | MIFMAOBMAOAMAPTCYP3A4 | |
| SCHEMBL29837280 | 0.89 | MIF (1.00) | MIFMAOBMAOAMAPTCYP3A4 | |
| SCHEMBL25035409 | 0.86 | CXCL12 (0.80) | MIFMAOBMAPTCYP3A4MEN1 | |
| SCHEMBL14160665 | 0.86 | MAPT (0.82) | MIFMAOBMAPTCYP3A4MEN1 | |
| SCHEMBL30274371 | 0.86 | CXCL12 (0.80) | MIFMAOBMAPTCYP3A4MEN1 | |
| SCHEMBL5724952 | 0.85 | MIF (0.76) | MIFMAOBMAOAMAPTCYP3A4 | |
| SCHEMBL5724935 | 0.85 | MIF (0.76) | MIFMAOBMAOAMAPTCYP3A4 | |
| Sappanone A 7-Methyl Ether SCHEMBL14479894 | 0.84 | MAPT (1.00) | MIFMAOBMAOAMAPTCYP3A4 | |
| SCHEMBL5725497 | 0.82 | MAPT (0.77) | MIFMAOBMAPTCYP3A4MEN1 | |
| Isobonducellin SCHEMBL31238399 | 0.81 | MAOB (1.00) | MIFMAOBMAPTCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20230096781-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | UNIVERSITY OF CINCINNATI (US) | 2023-03-30 | — | — | US | claimed |
| EP-4114963-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | University of Cincinnati (US) | 2023-01-11 | — | — | EP | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| EP-3370754-A2 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS | Acceleron Pharma Inc. (US) | 2018-09-12 | — | — | EP | claimed |
| US-20170274077-A1 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS | SURAGANI, RAJASEKHAR NAGA VENKATA SAI | 2017-09-28 | — | — | US | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| WO-2015051447-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2015-04-16 | — | — | WO | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3370754-B1 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS | ACCELERON PHARMA INC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4694880-A1 | POLYPHENOL-CONTAINING COMPOSITIONS FOR UPREGULATING GENE EXPRESSION | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2009065141-A1 | METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | MIF 1537/4885MAOB 1644/4885MAOA 1507/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | MIF 1739/4885MAOB 2282/4885MAOA 2349/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | MIF 1721/4885MAOB 2015/4885MAOA 2171/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MIF 4789/4885MAOB 704/4885MAOA 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.